Show simple item record

dc.contributor.authorGonzález-Álvaro, Isidoro
dc.contributor.authorMartínez-Fernández, Carmen
dc.contributor.authorDorantes-Calderón, Benito
dc.contributor.authorGarcía-Vicuña, Rosario
dc.contributor.authorHernández-Cruz, Blanca
dc.contributor.authorHerrero-Ambrosio, Alicia
dc.contributor.authorIbarra-Barrueta, Olatz
dc.contributor.authorMartín-Mola, Emilio
dc.contributor.authorMonte-Boquet, Emilio
dc.contributor.authorMorell-Baladrón, Alberto
dc.contributor.authorSanmartí, Raimon
dc.contributor.authorSanz-Sanz, Jesús
dc.contributor.authorDe-Toro, Javier
dc.contributor.authorVela, Paloma
dc.contributor.authorRomán Ivorra, José Andrés
dc.contributor.authorPoveda-Andrés, José Luis
dc.contributor.authorMuñoz-Fernández, Santiago
dc.date.accessioned2015-08-21T11:20:00Z
dc.date.issued2014-12-19
dc.identifier.citationGonzález-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200-1209.es_ES
dc.identifier.urihttp://hdl.handle.net/2183/14871
dc.description.abstract[Abstract] Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Results. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. Conclusion. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases.es_ES
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.relation.urihttp://dx.doi.org/10.1093/rheumatology/keu461es_ES
dc.rightsThis is a pre-copyedited, author-produced PDF of an article accepted for publication in Rheumatology following peer review. The version of the record is avaliable online at Oxford University Press.es_ES
dc.subjectRheumatoid arthritises_ES
dc.subjectPsoriatic arthritises_ES
dc.subjectAnkylosing spondolytises_ES
dc.subjectBiologicses_ES
dc.subjectOptimizationes_ES
dc.subjectDose reductiones_ES
dc.subjectbDMARDes_ES
dc.subjectcDMARDes_ES
dc.subjectRisk/benefit ratioes_ES
dc.titleSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
dc.date.embargoEndDate2015-12-19es_ES
dc.date.embargoLift2015-12-19


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record